IS6956A - Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því - Google Patents

Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því

Info

Publication number
IS6956A
IS6956A IS6956A IS6956A IS6956A IS 6956 A IS6956 A IS 6956A IS 6956 A IS6956 A IS 6956A IS 6956 A IS6956 A IS 6956A IS 6956 A IS6956 A IS 6956A
Authority
IS
Iceland
Prior art keywords
triacetetracyclo
pentaene
hexadeca
pharmaceutical compositions
citrate salt
Prior art date
Application number
IS6956A
Other languages
English (en)
Icelandic (is)
Inventor
James Johnson Phillip
Robert Rose Peter
Theophilus Wint Lewin
Robert Williams Glenn
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6956(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6956A publication Critical patent/IS6956A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
IS6956A 2001-05-14 2003-09-15 Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því IS6956A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29086301P 2001-05-14 2001-05-14
PCT/IB2002/001450 WO2002092597A1 (en) 2001-05-14 2002-04-26 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
IS6956A true IS6956A (is) 2003-09-15

Family

ID=23117854

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6956A IS6956A (is) 2001-05-14 2003-09-15 Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því

Country Status (37)

Country Link
US (1) US6787549B2 (OSRAM)
EP (1) EP1390366B1 (OSRAM)
JP (1) JP4137645B2 (OSRAM)
KR (1) KR20040008175A (OSRAM)
CN (1) CN1509288A (OSRAM)
AP (1) AP1429A (OSRAM)
AR (1) AR035889A1 (OSRAM)
AT (1) ATE303386T1 (OSRAM)
BG (1) BG108344A (OSRAM)
CA (1) CA2446988A1 (OSRAM)
CZ (1) CZ20032917A3 (OSRAM)
DE (1) DE60205888T2 (OSRAM)
DO (1) DOP2002000390A (OSRAM)
DZ (1) DZ3503A1 (OSRAM)
EA (1) EA005529B1 (OSRAM)
EE (1) EE200300557A (OSRAM)
ES (1) ES2245731T3 (OSRAM)
GT (1) GT200200081A (OSRAM)
HR (1) HRP20030911A2 (OSRAM)
HU (1) HUP0304085A3 (OSRAM)
IL (1) IL157874A0 (OSRAM)
IS (1) IS6956A (OSRAM)
MA (1) MA27021A1 (OSRAM)
MX (1) MXPA03010365A (OSRAM)
MY (1) MY134123A (OSRAM)
NO (1) NO20035035D0 (OSRAM)
NZ (1) NZ528209A (OSRAM)
OA (1) OA12600A (OSRAM)
PA (1) PA8545001A1 (OSRAM)
PE (1) PE20021095A1 (OSRAM)
PL (1) PL366774A1 (OSRAM)
SK (1) SK13372003A3 (OSRAM)
TN (1) TNSN03112A1 (OSRAM)
UA (1) UA73421C2 (OSRAM)
UY (1) UY27287A1 (OSRAM)
WO (1) WO2002092597A1 (OSRAM)
ZA (1) ZA200307234B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00459B (me) * 1997-12-31 2011-10-10 Pfizer Prod Inc Aril fuzirana azapoliciklična jedinjenja
PT1448235E (pt) 2001-11-30 2007-05-31 Pfizer Prod Inc Composições farmacêuticas orais de libertação controlada de 5,8,14-triazatetraciclo ( 10.3.1.0(2,11).0(4,9) ) - hexadeca-2(11),3,5,7,9-pentaeno.
JP2006528237A (ja) * 2003-05-20 2006-12-14 ファイザー・プロダクツ・インク バレニクリンの医薬組成物
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
JP2010527907A (ja) * 2006-11-09 2010-08-19 ファイザー・プロダクツ・インク ニコチン様中間体の多形体
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
EP2268639A2 (en) 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2376499B1 (en) * 2008-12-11 2015-02-25 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
WO2010143070A2 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
KR101673979B1 (ko) 2012-04-13 2016-11-08 리안윤강 진강 해신 파머수티컬 코. 엘티디. 화합물 jk12a 및 그 제조
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) * 2019-06-28 2020-12-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Microparticulate varenicline citrate
JP2023520164A (ja) * 2020-03-16 2023-05-16 チョンドゥー サイマウント ファーマテック カンパニー リミテッド ５－ｈｔ３受容体モジュレーター、結晶形態、それらの製造方法及び使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00459B (me) * 1997-12-31 2011-10-10 Pfizer Prod Inc Aril fuzirana azapoliciklična jedinjenja
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
EA200301120A1 (ru) 2004-02-26
EP1390366B1 (en) 2005-08-31
EA005529B1 (ru) 2005-04-28
AP1429A (en) 2005-06-13
AR035889A1 (es) 2004-07-21
GT200200081A (es) 2003-04-22
CN1509288A (zh) 2004-06-30
CZ20032917A3 (cs) 2004-07-14
SK13372003A3 (sk) 2004-08-03
DE60205888D1 (de) 2005-10-06
BG108344A (bg) 2004-12-30
ES2245731T3 (es) 2006-01-16
EE200300557A (et) 2004-04-15
HRP20030911A2 (en) 2004-02-29
PL366774A1 (en) 2005-02-07
JP2004529186A (ja) 2004-09-24
OA12600A (en) 2006-06-09
NO20035035L (no) 2003-11-13
TNSN03112A1 (fr) 2005-12-23
DE60205888T2 (de) 2006-07-06
PE20021095A1 (es) 2002-12-14
IL157874A0 (en) 2004-03-28
MA27021A1 (fr) 2004-12-20
KR20040008175A (ko) 2004-01-28
UA73421C2 (en) 2005-07-15
ZA200307234B (en) 2004-09-16
PA8545001A1 (es) 2003-09-05
DZ3503A1 (OSRAM) 2002-11-21
JP4137645B2 (ja) 2008-08-20
HUP0304085A2 (en) 2004-04-28
AP2002002522A0 (en) 2002-06-30
UY27287A1 (es) 2003-02-28
EP1390366A1 (en) 2004-02-25
US6787549B2 (en) 2004-09-07
NO20035035D0 (no) 2003-11-13
WO2002092597A1 (en) 2002-11-21
HUP0304085A3 (en) 2005-09-28
ATE303386T1 (de) 2005-09-15
CA2446988A1 (en) 2002-11-21
MXPA03010365A (es) 2004-03-16
MY134123A (en) 2007-11-30
NZ528209A (en) 2004-09-24
US20030149091A1 (en) 2003-08-07
DOP2002000390A (es) 2003-03-15

Similar Documents

Publication Publication Date Title
IS6957A (is) Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim
IS6956A (is) Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
NO20024175L (no) Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
IS7226A (is) Fjölbrigða form af rimonabant, framleiðsluaðferð og lyfjasamsetningar sem innihalda það
FI20011478A0 (fi) Farmaseuttinen koostumus
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
IS7796A (is) Lyfjasamsetningar sem samanstanda af súru lyfjasambandi, yfirborðsvirku efni og þolanlegum vatnsleysanlegum basa eða af basísku lyfjasambandi, yfirborðsvirku efni og þolanlegri vatnsleysanlegri sýru
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
DK1417206T3 (da) Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
PL374325A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
IS7051A (is) Lyfjasamsetningar
FI20022128L (fi) Farmaseuttinen koostumus
NO20020156L (no) Titanavledede forbindelser, fremstilling og anvendelse derav
NO20033120D0 (no) 2-arylimino-2,3-dihydrotiazolderivater, fremgangsmater for fremstilling derav og terapeutisk anvendelse derav
EP1389204A4 (en) NEW SULPHONAMIDE DERIVATIVES, THEIR INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPOUNDS
PT1358159E (pt) Tartrato e fosfato de 3,4 diaminopiridina, as suas composições farmacêuticas e as suas utilizações
NO20040912L (no) Beskyttede 3,5-dihydroksy-2,2-dimetyl-valeroamider for syntese av epotiloner og derivater derav, og fremgangsmate for fremstilling og andvendelse derav.
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
HUP0402149A3 (en) Water-soluble phenylpyridazine derivatives, their use and pharmaceutical compositions containing the same
NO20041878L (no) Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel.
DK1270562T3 (da) Cykliske alfa-amino-gamma-hydroxyamider, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger heraf
FI5468U1 (fi) Farmaseuttinen koostumus
IS6160A (is) Dífosfat salt af 4"-setinni-9-deoxó-9A-asa-9A-hómóerýtrómysín afleiðu og lyfjasamsetning þar af
DK1105101T3 (da) Fremgangsmåder og præparater til behandling af intracellulære infektioner